Diagnostic criteria for myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis, not otherwise specified (MDS/MPN-RS-T, NOS)
| Thrombocytosis, with platelet count ≥ 450 × 109/L |
| Anemia associated with erythroid-lineage dysplasia, with or without multilineage dysplasia, and ≥ 15% ring sideroblasts |
| Blasts < 1% in blood and < 5% in bone marrow |
| Presence of clonality: demonstration of a clonal cytogenetic abnormality and/or somatic mutation(s). In their absence, no history of recent cytotoxic or growth factor therapy that could explain the myelodysplastic/myeloproliferative features |
| Absence of SF3B1 mutation; no BCR::ABL1 or genetic abnormalities of myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; no t(3;3)(q21.3;q26.2), inv(3) (q21.3q26.2), or del(5q)* |
| No history of MPN, MDS, or other MDS/MPN |
| Thrombocytosis, with platelet count ≥ 450 × 109/L |
| Anemia associated with erythroid-lineage dysplasia, with or without multilineage dysplasia, and ≥ 15% ring sideroblasts |
| Blasts < 1% in blood and < 5% in bone marrow |
| Presence of clonality: demonstration of a clonal cytogenetic abnormality and/or somatic mutation(s). In their absence, no history of recent cytotoxic or growth factor therapy that could explain the myelodysplastic/myeloproliferative features |
| Absence of SF3B1 mutation; no BCR::ABL1 or genetic abnormalities of myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; no t(3;3)(q21.3;q26.2), inv(3) (q21.3q26.2), or del(5q)* |
| No history of MPN, MDS, or other MDS/MPN |
In a case that otherwise meets the diagnostic criteria for MDS with del(5q).